Lonza licenses GS system to Roche

Published: 19-Dec-2006
Research & Development

Lonza Group, the global life sciences company headquartered in Basel, Switzlerland, has established an agreement with Roche in which Lonza will license its GS (glutamine synthetase) Expression System and GS-CHO Protein Free System to Roche.


Lonza Group, the global life sciences company headquartered in Basel, Switzlerland, has established an agreement with Roche in which Lonza will license its GS (glutamine synthetase) Expression System and GS-CHO Protein Free System to Roche.

Roche is an existing customer of Lonza's GS system and they are now expanding its usage as one of their accepted platform technologies. The worldwide, non-exclusive umbrella research and license agreement enables Roche to use Lonza's proprietary GS system and GS-CHO Protein Free System as a platform for different applications within its own research and development centres, and to use it in the commercial manufacturing of certain products.

The GS (glutamine synthetase) Gene Expression System, owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Over 75 biotechnology and pharmaceutical companies and over 70 academic laboratories worldwide have successfully used the GS system, which has established itself as an industry standard, says Lonza.

The higher-yielding cell lines provide cost-efficient production of therapeutic proteins.

  • Companies:
  • Lonza
See more

You may also like

Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

Read more
The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Drug Delivery

Lonza and Iconovo collaborate to develop intranasal biologic for obesity

The two will aim to create an effective and stable inhaled formulation that can be used to treat obesity without the need for frequent injections
Manufacturing

Lonza's Synaffix and BigHat Biosciences team up to develop ADC pipeline programme

Synaffix's clinical-stage ADC platform technology will allow BigHat to expand and progress its ADC pipeline for oncological indications
Research & Development

AI-enabled route scouting: a faster and better way to successful synthesis

Despite the growing focus on biologics research, small molecules still make up the lion’s share of the medicines taken by patients every year
Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Research & Development

Overcome challenges and secure successful technology transfers of complex biological products in sterile manufacturing

The biopharmaceutical industry has seen many challenges in the last few years, spawned not just by a global pandemic but also the industry-wide disruption of operational and supply chain strategies that emerged in its aftermath...
Subscribe now